Wednesday, July 29, 2015 9:21:05 PM
But my brother is an optometrist and I thought I'd relay what he told me:
So far, it looks promising. I've "prescribed" it to about half a dozen patients so far and haven't heard any complaints. I spoke with the rep last week and she said that most offices who tried it got the initial 2 dozen units. Now some are beginning to reorder.
There is a lot of positive chatter on the vision websites about the product, some VERY positive. My daughter has been using it for acne and it works pretty nicely.
It's a novel product; a dilute form of chlorine that usually isn't stable. Avenova is a fairly stable version of it that is supposed to last about a month after opening. An effective antiinfective, not an antibiotic. Patients don't ask for it since they have no idea what it is or what it does. Heck, they don't even know they have a problem when they come into the office. It's up to me to identify patients who this may work on and have them understand and buy into the "every day" disinfection regimen for their dry eye or lid problems.
So far, it looks like a winner.
BTW, the rep said that NovaBay also manufacturers a version of the exact same product specifically for dermatologists (don't know the name). Also sold only in MD offices. It is doing well too.
Now if my brother is typical, then a lot of patients are slowly being diagnosed and exposed to the product. The sales team has done an excellent job meeting with MDs and ODs and the Avenova website points to every doctor who is prescribing.
It may be a slow ramp-up, but it seems to me that sales figures will only be growing. At .55 - .59 a share, I think this is an easy double in a year, when we have a few quarters of increasing sales to show. Now if only Nova Bay would produce a great infomercial, then people would be asking for it when they have eye-doctor appointments!
Recent NBY News
- Form PREM14A - Preliminary proxy statements relating to merger or acquisition • Edgar (US Regulatory) • 09/25/2024 09:17:41 PM
- Kuehn Law Encourages COFS, ARC, RFL, and NBY Investors to Contact Law Firm • PR Newswire (US) • 09/23/2024 01:27:00 PM
- Acumen Health Holdings ("Acumen") to Acquire the Avenova brand from NovaBay Pharmaceuticals • PR Newswire (US) • 09/20/2024 12:30:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 09/20/2024 12:08:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/20/2024 12:08:15 PM
- NovaBay Pharmaceuticals Signs Definitive Agreement to Sell its Avenova Assets • Business Wire • 09/20/2024 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2024 08:11:02 PM
- NovaBay Pharmaceuticals Reports Second Quarter 2024 Financial Results • Business Wire • 08/13/2024 08:05:00 PM
- NovaBay Pharmaceuticals to Hold Second Quarter 2024 Conference Call on August 13, 2024 • Business Wire • 08/01/2024 10:50:00 AM
- NovaBay Pharmaceuticals Reports Record Amazon Prime Day Sales • Business Wire • 07/30/2024 10:50:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/29/2024 08:25:15 PM
- NovaBay Pharmaceuticals Announces Closing of $3.87 Million Underwritten Public Offering, Including Partial Exercise of Overallotment Option • Business Wire • 07/29/2024 08:05:00 PM
- Form POS EX - Post-effective amendment adding exhibits to registration statement [Rule 462(d)] • Edgar (US Regulatory) • 07/26/2024 09:19:56 PM
- NovaBay Pharmaceuticals Announces Pricing of $3.5 Million Underwritten Public Offering • Business Wire • 07/26/2024 12:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 07/26/2024 04:15:03 AM
- NovaBay Pharmaceuticals Offers 20% Discounts on Avenova Eyecare Products During Amazon Prime Day • Business Wire • 07/16/2024 10:50:00 AM
- Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses • Edgar (US Regulatory) • 07/11/2024 12:50:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/11/2024 12:45:30 PM
- NovaBay Pharmaceuticals Reports Preliminary Second Quarter 2024 Net Revenue of $2.4 Million • Business Wire • 07/11/2024 10:50:00 AM
- Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses • Edgar (US Regulatory) • 07/10/2024 08:05:39 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 07/10/2024 01:30:17 PM
- NovaBay Pharmaceuticals Supports National Dry Eye Awareness Month with Multiple Avenova Product Promotions • Business Wire • 06/28/2024 10:50:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/14/2024 12:47:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/07/2024 11:30:13 AM
- NovaBay Pharmaceuticals Plan of Compliance Accepted by the NYSE American • Business Wire • 06/07/2024 10:50:00 AM
Lingerie Fighting Championships Signs Broadcast Deal With Maybacks Global Entertainment • BOTY • Sep 26, 2024 9:00 AM
Maybacks Global Entertainment and Lingerie Fighting Championships Enter Into Broadcast And Revenue Sharing Agreement • AHRO • Sep 26, 2024 8:30 AM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM